Galaxy Therapeutics Strengthens Leadership with New CMO
In a notable step forward, Galaxy Therapeutics has announced the appointment of Dr. Michael Alexander as Chief Medical Officer. This move aligns perfectly with the company’s objectives of enhancing its clinical and scientific teams as they work towards the development and eventual commercialization of their innovative SEAL™ Device, aimed at treating brain aneurysms.
Expertise of Dr. Michael Alexander
Dr. Alexander, a revered figure in neurosurgery, brings extensive experience and knowledge to Galaxy Therapeutics. With over two decades devoted to both clinical research and patient care, he is recognized as a dual-trained cerebrovascular neurosurgeon and neurointerventionalist. His previous roles at Cedars-Sinai in Los Angeles included Professor and Vice Chair of Neurosurgery, and Co-Director of the Comprehensive Stroke Center. His remarkable capability and reputation in the neurointerventional community underscore his fitting role as CMO.
A Legacy of Leadership
Before joining Galaxy Therapeutics, Dr. Alexander held prestigious positions at Duke University Medical Center and honed his skills during his fellowship at UCLA Medical Center. He will maintain his academic and clinical roles, contributing invaluable expertise to the strategic directions of Galaxy Therapeutics.
Significance of Dr. Alexander's Role
Dr. Sam Zaidat, President and CEO of Galaxy Therapeutics, expressed enthusiasm about Dr. Alexander’s addition to the executive team. He believes that Dr. Alexander’s unmatched experience and scientific inquiry will significantly propel the development of the SEAL device, which is designed to cater to complex aneurysm cases. Their collaboration promises to be a catalyst for fostering innovation and enhancing patient outcomes in neurosurgery.
Dr. Alexander's Contributions to Neurosurgery
Throughout his career, Dr. Alexander has been actively involved in over 45 clinical trials and has continuously secured funding from the National Institutes of Health for nearly two decades. Additionally, he has held pivotal roles within the Society of NeuroInterventional Surgery as a Past President and has significantly contributed to the academic community through co-authoring two textbooks and publishing over 160 peer-reviewed articles focused on neurovascular diseases.
About Galaxy Therapeutics
Galaxy Therapeutics is a private, clinical-stage medical device company focused on innovative treatments for brain aneurysms. Founded by a team of neurointerventional physicians, the company has developed unique implant technology and holds multiple patents across major markets, including the U.S., EU, and China. Headquartered in Milpitas, California, Galaxy Therapeutics pursues several clinical programs worldwide with a commitment to providing effective, evidence-based solutions for both physicians and patients.
Frequently Asked Questions
What position has Dr. Michael Alexander been appointed to at Galaxy Therapeutics?
Dr. Michael Alexander has been appointed as the Chief Medical Officer of Galaxy Therapeutics.
What is the SEAL device designed for?
The SEAL device is designed to treat brain aneurysms, including complex cases.
What notable roles did Dr. Alexander previously hold?
Dr. Alexander has held significant roles at Cedars-Sinai, including Professor and Vice Chair of Neurosurgery.
How long has Dr. Alexander been involved in clinical research?
Dr. Alexander has over 20 years of experience in clinical research and patient care.
What is the focus of Galaxy Therapeutics as a company?
Galaxy Therapeutics focuses on developing innovative treatments for brain aneurysms using advanced medical device technology.
